What is Stoke Therapeutics, Inc.'s deferred revenue?

Stoke Therapeutics, Inc. (STOK) reported deferred revenue of -$2.19M in Q1 2026.

How has Stoke Therapeutics, Inc.'s deferred revenue changed year-over-year?

Stoke Therapeutics, Inc.'s deferred revenue decreased by 123.3% year-over-year, from $9.43M to -$2.19M.

Stoke Therapeutics, Inc. STOK Deferred Revenue

Deferred Revenue at other companies

Sarepta Therapeutics, Inc.SRPT

——

Tango TherapeuticsTNGX

——

Relay Therapeutics, Inc.RLAY

——

Other financials

Income statement

See full

Revenue$6.2M-96.1%

Operating income-$53.4M-148%

Net income-$50.0M-144%

EPS (diluted)-$0.79-142%

Balance sheet

See full

Cash & equivalents$155.7M-43.4%

Total debt$3.4M-42.5%

Total equity$394.9M+12.8%

Total assets$443.3M+8.9%

Cash flow

See full

Operating cash flow-$60.6M-146%

CapEx$353.0K+132%

Free cash flow-$60.9M-146%

Valuation

See full

Market cap$1.94B+436%

Enterprise value$1.79B+1,855%

P/S60.4×+58.5×

Profitability

See full

Operating margin-577.5%-597pp

Net margin-529.2%-556pp

FCF margin36.2%+18.4pp

Returns & leverage

See full

Return on equity-45.6%-66.1pp

Debt / equity0×0.0×

Current ratio9×+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Stoke Therapeutics, Inc.'s deferred revenue?: Stoke Therapeutics, Inc. (STOK) reported deferred revenue of -$2.19M in Q1 2026.
How has Stoke Therapeutics, Inc.'s deferred revenue changed year-over-year?: Stoke Therapeutics, Inc.'s deferred revenue decreased by 123.3% year-over-year, from $9.43M to -$2.19M.